Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937986 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL2152762 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL11726308 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL1937657 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL11726259 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL11810751 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL12669343 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL11125409 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL1937316 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL11808849 | 1.00 | EPHX1 (0.45) | EPHX1CASP2ZDHHC20ZDHHC2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066623-B1 | PROCESS FOR PRODUCING 1-(3,4-DICHLOROBENZYL)-5-OCTYLBIGUANIDE OR A SALT THEREOF | OTSUKA PHARMA CO LTD (JP) | 2013-06-19 | — | — | EP | claimed |
| US-7868207-B2 | Process for producing 1-(3,4-dichlorobenzyl)-5-octylbiguanide or a salt thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-11 | — | — | US | claimed |
| US-20090270653-A1 | PROCESS FOR PRODUCING 1-(3,4-DICHLOROBENZYL)-5-OCTYLBIGUANIDE OR A SALT THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | claimed |
| EP-2066623-A1 | PROCESS FOR PRODUCING 1-(3,4-DICHLOROBENZYL)-5-OCTYLBIGUANIDE OR A SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-06-10 | — | — | EP | claimed |
| WO-2008026757-A1 | PROCESS FOR PRODUCING 1-(3,4-DICHLOROBENZYL)-5-OCTYLBIGUANIDE OR A SALT THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-03-06 | — | — | WO | claimed |
| EP-0507317-B1 | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-01-15 | — | — | EP | claimed |
| US-4347310-A | INCREASED PHOTOSENZITIVITY USING GUANIDINE DERIVTIVES AS SENSITIZERS; PHOTOSTABILITY; STORAGE STABILITY | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1982-08-31 | — | — | US | claimed |
| EP-2066623-B1 | PROCESS FOR PRODUCING 1-(3,4-DICHLOROBENZYL)-5-OCTYLBIGUANIDE OR A SALT THEREOF | OTSUKA PHARMA CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| CN-101506152-B | Process for producing 1- (3, 4-dichlorobenzyl) -5-octylbiguanide or salt thereof | OTSUKA PHARMA CO LTD | 2012-11-21 | — | — | CN | disclosed |
| US-20110207926-A1 | NOVEL DIHYDROTRIAZINE DERIVATIVE | HAMARI CHEMICALS, LTD. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2332925-A1 | NOVEL DIHYDROTRIAZINE DERIVATIVE | Hamari Chemicals, Ltd. (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-7868207-B2 | Process for producing 1-(3,4-dichlorobenzyl)-5-octylbiguanide or a salt thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-7868207-B2 | Process for producing 1-(3,4-dichlorobenzyl)-5-octylbiguanide or a salt thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-0507317-B1 | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives | OTSUKA PHARMA CO LTD (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0507317-A2 | Biguanide derivatives, manufacturing method thereof, and disinfectants containing the derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
| US-4347310-A | INCREASED PHOTOSENZITIVITY USING GUANIDINE DERIVTIVES AS SENSITIZERS; PHOTOSTABILITY; STORAGE STABILITY | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1982-08-31 | — | — | US | disclosed |
| US-4045483-A | BACTERICIDES, FUNGICIDES | STERLING DRUG INC. (US) | 1977-08-30 | — | — | US | disclosed |
| US-4009163-A | BACTERICIDES, FUNGICIDES | STERLING DRUG INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-3996232-A | ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3988370-A | BACTERICIDES, FUNGICIDES | STERLING DRUG INC. (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207926-A1 | NOVEL DIHYDROTRIAZINE DERIVATIVE | QDPR, DRD4, DRD1 | EPHX1 4731/4885CASP2 459/4885ZDHHC20 3377/4885 |
| US-20090270653-A1 | PROCESS FOR PRODUCING 1-(3,4-DICHLOROBENZYL)-5-OCTYLBIGUANIDE OR A SALT THEREOF | SLC6A9, CA9, ALKBH1 | EPHX1 654/4885CASP2 3173/4885ZDHHC20 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.